An overview on the biological activity and anti-cancer mechanism of lovastatin.

Lovastatin, a secondary metabolite isolated from fungi, is often used as a representative drug to reduce blood lipid concentration and treat hypercholesterolemia. Its structure is similar to that of HMG-CoA. Lovastatin inhibits the binding of the substrate to HMG-CoA reductase, and strongly competes with HMG-CoA reductase (HMGR), thereby exerting a hypolipidemic effect. Further, its safety has been confirmed in vivo and in vitro. Lovastatin also has anti-inflammatory, anti-cancer, and neuroprotective effects. Therefore, the biological activity of lovastatin, especially its anti-cancer effect, has garnered research attention. Several in vitro studies have confirmed that lovastatin has a significant inhibitory effect on cancer cell viability in a variety of cancers (such as breast, liver, cervical, lung, and colon cancer). At the same time, lovastatin can also increase the sensitivity of some types of cancer cells to chemotherapeutic drugs and strengthen their therapeutic effect. Lovastatin inhibits cell proliferation and regulates cancer cell signaling pathways, thereby inducing apoptosis and cell cycle arrest. This article reviews the structure, biosynthetic pathways, and applications of lovastatin, focusing on the anti-cancer effects and mechanisms of action. Copyright © 2021 Elsevier Inc. All rights reserved.

Citation

Liguo Xie, Guodong Zhu, Junjie Shang, Xuemei Chen, Chunting Zhang, Xiuling Ji, Qi Zhang, Yunlin Wei. An overview on the biological activity and anti-cancer mechanism of lovastatin. Cellular signalling. 2021 Nov;87:110122

Mesh Tags

Substances

PMID: 34438015

search → result